QHSLab Inc (OTCQB: USAQ) is a digital health company that provides medical device technology and software-as-a-service tools enabling independent primary care physicians to identify, document, and manage underdiagnosed chronic and behavioral health conditions. Revenue comes from recurring subscription and service fees charged to participating medical practices on a per-patient, per-month basis, covering platform access, digital care workflows, and support services. The company also sells FDA-cleared allergy diagnostic devices to practices under its AllergiEnd brand. QHSLab does not bill patients or payers directly; instead, participating practices bill applicable payers for clinical services rendered using the platform. The company targets independent, physician-led primary care practices that control their own clinical workflows and bill Medicare and commercial insurance. As of the 10-K filed March 30, 2026, common stock trades on the OTCQB venture market under the symbol USAQ. The company has neither declared nor paid cash dividends as of the filing date.
- Revenue model
- Recurring subscription and service fees charged to participating medical practices on a per-patient, per-month basis, structured as flat amounts tied to platform access, digital care workflows, and support services. Additional revenue from the sale of FDA-cleared allergy diagnostic devices to practices under the AllergiEnd offering. Revenue varies with patient participation, service utilization, and number of active enrolled patients per practice. The company does not bill patients or payers directly.
- Products and services
- Digital health platform supporting behavioral health screening, chronic disease identification and care management, remote patient monitoring, and non-face-to-face clinical decision support for primary care practices. AllergiEnd is the company's allergy diagnostics and treatment offering, combining FDA-cleared diagnostic devices with allergy screening and follow-up workflows integrated into the digital platform. Platform workflows include patient capture, stratification, escalation, documentation, dashboarding, and reimbursement support.
- Customers and end markets
- Independent, physician-led primary care practices that control their own clinical workflows, bill Medicare and commercial insurance, manage diverse patient populations, and face operational constraints related to screening and follow-up care. End markets include chronic disease management, behavioral health, allergy diagnostics, preventive care, and remote patient monitoring within primary care.
- Value-chain role
- Technology and software vendor sitting between medical device manufacturers and primary care practices. Provides the platform, devices, training, and workflow infrastructure that enables practices to expand reimbursable services. Acts as a business associate under HIPAA, handling protected health information on behalf of covered entity clients.
- Geographic exposure
- United States. Subject to U.S. federal and state laws and regulations including HIPAA, Stark Law, Anti-Kickback Act, and the False Claims Act. No specific geographic revenue breakdown disclosed in the excerpts.
- Competitors
- Point-solution digital health vendors focused on single conditions, Behavioral health screening and care management platforms, Chronic care management software providers, EHR-embedded tools and third-party add-ons, Allergy diagnostic device manufacturers and specialty-focused providers
